Tempest Therapeutics Appoints Drake Richey and Dr. John Yee to Board (Effective June 4)
TPST•Tempest Therapeutics appointed finance expert Drake Richey and medical affairs veteran Dr. John Yee to its Board of Directors effective June 4, 2026. Richey’s corporate finance background and Dr. Yee’s leadership at Vertex, AstraZeneca, and Apnimed aim to support growth and disciplined capital allocation for its CAR-T therapy pipeline.
1. Board Appointments
On June 4, 2026, Tempest Therapeutics added two independent directors—Drake Richey and John Yee, MD, MPH—to its Board of Directors. These appointments expand the board’s expertise in corporate finance and medical affairs support.
2. Directors' Backgrounds
Drake Richey, president of Bush & Company and former VP at Wells Fargo and Fitch Ratings director, brings deep financial advisory and risk management experience. John Yee, MD, MPH, former CMO at Sobi North America and Global Head of Medical Affairs at Vertex, adds decades of clinical leadership in oncology and evidence-based medicine.
3. Implications for Growth
The new board members are expected to guide disciplined capital allocation and strategic growth of Tempest’s CAR-T cell therapy pipeline. Their combined expertise may enhance governance and accelerate development of treatments for patients with advanced cancers.
